文献速递肿瘤 PET/CT甲状腺核医学

B7H3靶向分子影像用于乳腺癌高特异性诊断及无创检测

B7H3-Targeted Molecular Imaging for Highly Specific Diagnosis and In Vivo Noninvasive Detection of B7H3 in Breast Cancer.
PubMed 文献 · J Nucl Med · 2026-10-15

B7H3免疫组化阳性率84%,[68Ga]Ga-B7H3-BCH对157个病灶检出率96.8%高于[18F]FDG的92.4%,8例分期或治疗改变。

要点

  • [68Ga]Ga-B7H3-BCH PET/CT对乳腺癌病灶检出率高于[18F]FDG。
  • 骨转移灶摄取最高,中位SUVmax为10.9。
  • 激素受体阳性/HER2阴性病灶B7H3阳性率及摄取最高。

核心结论

  • [68Ga]Ga-B7H3-BCH PET/CT对晚期乳腺癌分期及无创B7H3筛查具有高敏感性,可能影响临床决策并呈现亚型特异性摄取。

主要发现

  • 免疫组化检测B7H3阳性样本占84%。
  • [68Ga]Ga-B7H3-BCH在157个病灶中检出率96.8%,高于[18F]FDG的92.4%。
  • 强阳性病灶中位SUVmax为9.5,骨转移灶摄取最高(中位SUVmax 10.9)。
  • 影像检查使8例患者的分期或治疗发生改变。
  • 激素受体阳性/人表皮生长因子受体2阴性病灶B7H3阳性率最高(87.5%),中位SUVmax为10.5。

关键数值与推荐

  • B7H3免疫组化阳性率84%(25例样本)。
  • [68Ga]Ga-B7H3-BCH病灶检出率96.8% vs [18F]FDG 92.4%(157个病灶)。
  • 强阳性病灶中位SUVmax 9.5,骨转移灶中位SUVmax 10.9。
  • 激素受体阳性/HER2阴性病灶B7H3阳性率87.5%,中位SUVmax 10.5。

临床怎么用

  • 可用于乳腺癌分期及无创评估B7H3表达,尤其激素受体阳性/HER2阴性亚型。
  • 影像结果可能改变8例患者的分期或治疗决策,提示其对临床管理有潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B7 homolog 3 (B7H3) is widely expressed in solid tumors, but its role in the diagnosis of breast cancer is unclear. We aimed to evaluate the diagnostic performance of [68Ga]Ga-B7H3-BCH PET/CT in breast cancer patients. Methods: Thirty patients with diverse subtypes of breast cancer underwent both [68Ga]Ga-B7H3-BCH and [18F]FDG PET/CT. Immunohistochemical staining for B7H3 was performed in 25 patients. Results: B7H3 positivity was detected in 84% of samples by immunohistochemistry. [68Ga]Ga-B7H3-BCH demonstrated a higher lesion detection rate compared with [18F]FDG (96.8% vs. 92.4%) among 157 lesions. Median SUVmax was 9.5 in strongly positive lesions; bone metastases had the highest uptake (median SUVmax, 10.9). Imaging resulted in changing the stage or treatment in 8 patients. Hormone receptor-positive/human epidermal growth factor receptor 2-negative lesions showed the highest B7H3 positivity (87.5%) and uptake (median SUVmax, 10.5). Conclusion: [68Ga]Ga-B7H3-BCH PET/CT offers high sensitivity for staging advanced breast cancer and noninvasive B7H3 screening. It may influence clinical decisions and appears to reveal subtype-specific uptake, with a tendency to favor hormone receptor-positive/human epidermal growth factor receptor 2-negative disease.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Xia L, Gong Y, He C, et al. B7H3-Targeted Molecular Imaging for Highly Specific Diagnosis and In Vivo Noninvasive Detection of B7H3 in Breast Cancer. J Nucl Med. 2026. PMID: 42880960. doi:10.2967/jnumed.126.272939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。